FDA seeks public input on clinical trial design for ibogaine drug products
The U.S. Food and Drug Administration announced a request for information on approaches for designing early-phase clinical trials of ibogaine drug products, marking the first government-funded trials of the psychedelic drug to treat opioid addiction and post-traumatic stress disorder. The agency is seeking public comments, data, and feedback on safety protocols for the studies.
